Artificial Lung Market Size Projected to Reach $6.52 billion by 2034 | 10.61%

According to Straits Research, the global artificial lung market size was valued at $2.63 billion in 2025 and is expected to grow from $2.90 billion in 2026 to $6.50 billion by 2034, registering a CAGR of 10.61% during the forecast period (2026–2034

The global artificial lung market is growing consistently, propelled by the escalating prevalence of chronic respiratory disorders, heightened need for sophisticated respiratory support systems, and continuous innovations in extracorporeal life support technology.

Artificial lungs are essential for managing illnesses such as ARDS and COPD and assisting transplant recipients. Their utilisation in ICUs, surgical facilities, and transplant programs is expanding due to heightened healthcare expenditure, awareness of organ support technology, and expanded application of ECMO in critical care, particularly following COVID-19. Advancements in membrane oxygenators, artificial intelligence monitoring, and biocompatible materials improve safety and efficiency, while investigations into bioartificial lungs and regenerative scaffolds are broadening prospects.

Market Dynamics

Portable ECMO systems drive market growth

The primary catalyst for the artificial lung industry is the growing utilisation of compact, transportable extracorporeal membrane oxygenation (ECMO) equipment, facilitating enhanced respiratory support beyond conventional ICU environments. Healthcare systems are encountering an increased need for adaptable, mobile life-support technology, prompting advancements in portable artificial lung devices that transform critical care and emergency response.

• In December 2024, Yale New Haven Health became the inaugural health system in the United States to implement Medtronic’s FDA-approved VitalFlow ECMO System for inter-hospital patient transportation. The device, intended for extended respiratory and circulatory assistance, was effectively utilised during the transition from Greenwich Hospital to Yale New Haven Hospital.

As hospitals, trauma centres, and transplant networks increasingly pursue scalable, transportable solutions for patients with acute respiratory distress or chronic pulmonary failure, the demand for advanced artificial lung systems intensifies.

Advancement of portable, automated ECMO systems creates tremendous opportunities

An intriguing possibility in the artificial lung industry arises from university-led engineering initiatives centred on miniaturisation and automation, highlighting novel avenues for patient-friendly, mobile respiratory support solutions.

• In May 2025, a group of biomedical engineering students at Vanderbilt University, in partnership with Vanderbilt University Medical Center, presented a senior-design prototype for an automated portable ECMO system. This device incorporates an oxygen concentrator, capnography-based CO₂ detection, and servo-motor-driven controls to dynamically regulate gas exchange, minimising dependence on physician intervention and facilitating improved mobility and rapid response in critical scenarios.

As clinical validation and commercialisation channels expand, these academic advances present a scalable opportunity: developers of artificial lungs can partner with universities and startups to expedite the advancement of next-generation portable respiratory technology.

Regional Analysis

North America dominates the artificial lung market, bolstered by its sophisticated healthcare infrastructure and robust incorporation of life-saving technologies within intensive care units. The area exhibits significant clinical utilisation of artificial lungs, especially in treating severe respiratory failure and cardiovascular disorders. Healthcare institutions continually emphasise innovation, dependability, and adherence to regulations, promoting the early adoption of extracorporeal and implantable artificial lung systems. Furthermore, hospitals and research organisations in the region uphold established guidelines for patient monitoring, surgical procedures, and post-implant care, facilitating the seamless integration of artificial lung devices.

Market Segments

1. By Product Type
   1. Extracorporeal Membrane Oxygenation (ECMO) Systems
   2. Paracorporeal Artificial Lungs
   3. Intracorporeal Artificial Lungs
   4. Membrane Oxygenators
   5. Portable Artificial Lungs
2. By Application
   1. Bridge-to-Transplantation
   2. Bridge-to-Recovery
   3. ECMO-assisted Ventilation
   4. Pulmonary Rehabilitation
   5. Long-term Support for Chronic Lung Diseases
3. By Distribution Channel
   1. Hospital-based Procurement
   2. Direct Tenders and Contracts
   3. Group Purchasing Organizations (GPOs)
   4. Online Procurement Platforms (limited role)
   5. Third-party Distributors (emerging in select regions)
4. By End-User
   1. Tertiary Care Hospitals
   2. Transplant Centers
   3. Cardiac and Pulmonary ICUs
   4. Research Institutions and Clinical Trial Sites
   5. Specialty Respiratory Clinics
5. By Region
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Latin America
   5. The Middle East and Africa